[1] 代庆红,王忠东.中国糖尿病的现状调查[J].中国医药指南,2011, 9(13):206-208.[2] Bassetti M,Trecarichi EM,Mesini A,et al.Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia.Clin Microbiol Infect. 2012;18(9): 862-869.[3] Miras AD,Risstad H,Baqai N,et al.Application of the International Diabetes Federation and American Diabetes Association criteria in the assessment of metabolic control after bariatric surgery.Diabetes Obes Metab.2014; 16(1): 86-89.[4] 偶晨,景欣悦,卢圣锋,等.不同剂量罗格列酮对2型糖尿病大鼠的体重增加效应[J].中国老年学,2015,35(23):6672-6674.[5] 潘成霞.罗格列酮钠治疗2型糖尿病前后患者血清CRP、IL-6、TNF-α水平变化[J].中国冶金工业医学杂志,2010,27(4): 476-477.[6] 梁海霞.马来本罗格列酮钠和罗格列酮钠治疗2型糖尿病的疗效及安全性评价[J].山西医药杂志,2011,40(2):191-193.[7] Tang Y,Gan X,Cheheltani R,et al.Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model.Nanomedicine.2014;10(8):1711 -1718.[8] Russo V,Young S,Hamilton A,et al.Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury.Biomaterials.2014;35(13):3956-3974.[9] Yeh TS,Fang YHD,Lu CH,et al. Baculovirus-transduced, VEGF-expressing adipose-derived stem cell sheet for the treatment of myocardium infarction.Biomaterials. 2014; 35(1):174-184.[10] Ciceri F,Piemonti L.Bone Marrow and Pancreatic Islets:An Old Story With New Perspectives.Cell Transplant.2010; 19(12):1511-1522.[11] Alipio Z,Liao W,Roemer EJ,et al.Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells.Proc Natl Acad Sci U S A.2010;107(30):13426-13431. [12] Prabakar KR,Domínguez-Bendala J,Molano RD,et al. Generation of glucose-responsive,insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells.Cell Transplant.2011;21(6):1321-39.[13] Amin AH,Elmageed ZYA,Nair D,et al.Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice.Lab Invest. 2010;90(7):985-996. [14] Sterodimas A,De FJ,Nicaretta B,et al.Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications.J Plast Reconstr Aesthet Surg.2010;63(11): 1886-1892.[15] Yue Y,Zhang P,Liu D,et al.Hypoxia Preconditioning Enhances the Viability of ADSCs to Increase the Survival Rate of Ischemic Skin Flaps in Rats.Aesthetic Plast Surg.2013; 37(1): 159-170.[16] Zhu P,Liu J,Shi J,et al.Melatonin protects ADSCs from ROS and enhances their therapeutic potency in a rat model of myocardial infarction.JCell Mol Med.2015;19(9):2232-2243.[17] Chan TM,Harn HJ,Lin HP,et al.The use of ADSCs as a treatment for chronic stroke.Cell Transplant. 2014;23(4-5): 541-547.[18] Jin Y,Zhang W,Liu Y,et al.rhPDGF-BB via ERK pathway osteogenesis and adipogenesis balancing in ADSCs for critical-size calvarial defect repair.Tissue Engi Part A.2014; 20(23-24):3303-3313.[19] 臧丽,谢宗燕,刘杰杰,等.骨髓和脂肪来源的间充质干细胞治疗2型糖尿病的疗效比较[J].解放军医学杂志,2016,41(7):534-538.[20] 谢敏,郝好杰,刘杰杰,等.脂肪间充质干细胞促进肝脏糖酵解对2型糖尿病大鼠高血糖的改善作用研究[J].解放军医学杂志,2016, 41(7):539-543.[21] 李冬松,李叔强,王苹,等.高糖、糖基化终末产物对人脂肪干细胞成骨分化能力的影响[J].中华实验外科杂志, 2010,27(11): 1592-1594.[22] 转黎,王涛,李明超,等.氯甲基苯甲酰氨和5-乙炔基-2'-脱氧尿嘧啶核苷标记示踪大鼠脂肪干细胞的研究[J].中华实验外科杂志, 2013,30(8):1701-1703.[23] 尚萍.脂肪干细胞治疗促进组织血管化的旁分泌机制中细胞因子来源的探讨[D].南昌大学,2012.[24] 黄昕昕.大鼠不同部位来源脂肪源性干细胞的增殖能力比较及CM-Dil体外标记研究[D].大连医科大学,2012.[25] 孙煦勇,秦科,农江,等.人胰岛在分离、纯化过程中的细胞凋亡及氧化损伤[J].中华器官移植杂志,2011,32(8):502-505.[26] 徐爱晶,陈志红,田飞,等.IL-10基因对糖尿病大鼠胰岛β细胞凋亡的保护作用[J].现代生物医学进展,2014,14(4):671-675.[27] Varga T,Czimmerer Z,Nagy L.PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation.Biochim Biophys Acta. 2011; 1812(8):1007-1022.[28] Wang YX.PPARs:diverse regulators in energy metabolism and metabolic diseases.Cell Res.2010;20(2):124-137.[29] Li P,Siersbak M,Mandrup S.PPARs:fatty acid sensors controlling metabolism.Semin Cell Dev Biol. 2012;23(6): 631-639.[30] Lu M,Sarruf DA,Talukdar S,et al.Brain PPAR-[gamma] promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.Nat Med.2011;17(5):618-622.[31] 李文君,和明丽,程晓芸,等.噻唑烷二酮类药物对GK大鼠胰岛B细胞凋亡的影响[J].第二军医大学学报,2010,31(6):604-607.[32] 张宁,孟爱民,王莉莉.选择性PPARγ调节剂治疗二型糖尿病的分子机制研究进展[J].中国药理学通报,2013,29(2):157-160.[33] 李晓岩.罗格列酮钠治疗2型糖尿病长期效果观察[J].中国现代药物应用,2012,6(2):83-84.[34] 许评,刘建安.脂肪间充质干细胞移植治疗1型糖尿病[J].临床普外科电子杂志,2015,3(1):1-6.[35] 刘艳翠,李文媛,王莹,等.脂肪源性干细胞移植对脑缺血/再灌注损伤大鼠趋化因子及其受体表达影响的实验研究[J].医学综述, 2012,18(16):2645-2647.[36] 王哲,刘晓玉,张殿宝,等.普罗布考对高糖诱导的脂肪间充质干细胞损伤的保护作用[J].中国医科大学学报,2014,43(7):615-620.[37] 毕惠娟,王健.CXCR1、CXCR2及其配体的结构和功能[J].免疫学杂志,2010,26(12):1091-1095. |